Celiac Disease Prevention
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Celiac disease is an autoimmune disease induced by wheat gluten. Destruction of epithelial cells and microvilli on gut mucosa is causing a "flat mucosa" and an absorption defect. The diagnosis is based on typical microscopical finding in biopsy specimens but serum antibodies to tissue transglutaminase and certain gliadin peptides are strongly associated with the pathology. Severe diarrhoea associated with growth disturbance in infancy was historically characterising the disease but is nowadays rare. Clinically more mild forms including silent disease are very common. Studies based on antibody screening and biopsies done in autoantibody positive subjects have confirmed a frequency of about 1-2% in adult population. Undiagnosed disease is associated with deficiencies of nutrients and vitamins leading to various chronic symptoms like anaemia, osteoporosis and general fatigue. It has also been recently found that undiagnosed celiac disease may be associated with general underachievement in society probably associated with common psychological symptoms like fatigue and depression during the adolescence. The disease is treated by complete elimination of wheat, rye and barley in the diet, which is laborious and causing considerable extra costs in nutrition.
Much progress has been recently made in understanding of the genetic background and immune markers associated with the disease as well as in understanding those patterns of gluten introduction in infancy, which might be connected to a high disease risk. Our aim in this study is in the first phase to identify children at high genetic risk (around 10%) and in a follow-up study to define:
- Are the age, dose of gluten and presence of simultaneous breast feeding at the introduction of gluten associated with the risk of celiac disease?
- Is it possible to decrease the frequency of celiac disease by nutritional counselling?
- Is it possible to predict development of celiac disease by immunological tests before the development of mucosal lesion
If we can confirm, that optimising the conditions at the introduction of wheat gluten in infancy diet significantly reduces the disease incidence, will this have an important effect on the nutritional recommendations concerning the diet in infancy. Combining genetic screening and immunological tests might also offer a way to reduce the frequency of celiac disease and help in early diagnosis and organisation of an adequate treatment
| Condition | Intervention |
|---|---|
|
Celiac Disease |
Other: Optimal gluten introduction |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single Blind (Subject) Primary Purpose: Prevention |
| Official Title: | Prevention of Celiac Disease in Children at Genetic Risk - Optimized Introduction of Gluten and Follow-up of Immunization |
- development of transglutaminase antibodies [ Time Frame: 2-4 year age ] [ Designated as safety issue: No ]
- gliadin peptide antibodies [ Time Frame: 2-4 years ] [ Designated as safety issue: No ]
- mucosal biopsy in TGA positive childre [ Time Frame: 2-4 years ] [ Designated as safety issue: No ]
| Enrollment: | 168 |
| Study Start Date: | October 2007 |
| Estimated Study Completion Date: | December 2014 |
| Estimated Primary Completion Date: | August 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Optimization of gluten introduction by nutritional councelling
|
Other: Optimal gluten introduction
Optimization of gluten introduction by nutritional counselling
|
|
No Intervention: 2
No specific nutritional councelling. Follow-up of gluten introduction
|
Eligibility| Ages Eligible for Study: | up to 2 Months |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Presence of HLA-risk alleles DQA1*05 and DQB1*02
Exclusion Criteria:
- Lack of these HLA risk alleles
Contacts and Locations| Finland | |
| Kuopio University Hospital | |
| Kuopio, Finland, FIN-70211 | |
| Principal Investigator: | Jorma Ilonen, MD | University of Eastern Finland |
More Information
No publications provided
| Responsible Party: | Kuopio University Hospital |
| ClinicalTrials.gov Identifier: | NCT00617838 History of Changes |
| Other Study ID Numbers: | KUH5021612 |
| Study First Received: | February 6, 2008 |
| Last Updated: | April 3, 2012 |
| Health Authority: | Finland: Ethics Committee |
Keywords provided by Kuopio University Hospital:
|
Celiac disease genetic risk gluten introduction predicting antibodies |
Additional relevant MeSH terms:
|
Celiac Disease Malabsorption Syndromes Intestinal Diseases |
Gastrointestinal Diseases Digestive System Diseases Metabolic Diseases |
ClinicalTrials.gov processed this record on May 21, 2013